Herb-drug interactions: Challenges and opportunities for improved predictions

Drug Metabolism and Disposition

Volumn 42, Issue 3, 2014, Pages 301-317

  Brantley, Scott J ^a   Argikar, Aneesh A ^b   Lin, Yvonne S ^c   Nagar, Swati ^b   Paine, Mary F ^d  

^a University of North Carolina   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GOVERNMENT REGULATION; HERB-DRUG INTERACTIONS; HUMANS; LEGISLATION, DRUG; MILK THISTLE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PLANT PREPARATIONS; SILYMARIN; STILBENES;

EID: 84893839263     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055236     Document Type: Review

References (202)

1. Agarwal R, Agarwal C, Ichikawa H, Singh RP, and Aggarwal BB (2006) Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26 (6B):4457-4498.
2. Aggarwal BB and Shishodia S (2006) Resveratrol in Health and Disease, CRC Taylor & Francis, Boca Raton, FL.
3. Aires V, Limagne E, Cotte AK, Latruffe N, Ghiringhelli F, and Delmas D (2013) Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res 57:1170-1181.
4. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, El-Eraky WI, and El-Shemy HA (2011) Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44:591-601.
5. Alfaras I, Pérez M, Juan ME, Merino G, Prieto JG, Planas JM, and Alvarez AI (2010) Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J Agric Food Chem 58:4523-4528.
6. Annaba F, Sarwar Z, Kumar P, Saksena S, Turner JR, Dudeja PK, Gill RK, and Alrefai WA (2008) Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts. Am J Physiol Gastrointest Liver Physiol 294:G489-G497.
7. Annaert PP, Turncliff RZ, Booth CL, Thakker DR, and Brouwer KL (2001) P-glycoproteinmediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab Dispos 29:1277-1283.
8. Arnaud O, Koubeissi A, Ettouati L, Terreux R, Alamé G, Grenot C, Dumontet C, Di Pietro A, Paris J, and Falson P (2010) Potent and fully noncompetitive peptidomimetic inhibitor of multidrug resistance P-glycoprotein. J Med Chem 53:6720-6729.
9. Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Mérillon JM, Magdalou J, and Sabolovic N (2001) Regioselective and stereospecific glucuronidation of trans-and cis-resveratrol in human. Arch Biochem Biophys 393:281-289.
10. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker RH, Beckurts KT, Lang W, Hunz M, and Fuhr U (2000) Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 86:250-256.
11. Bent S (2008) Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 23: 854-859.
12. Berge G, Øvrebø S, Botnen IV, Hewer A, Phillips DH, Haugen A, and Mollerup S (2004) Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cells. Br J Cancer 91:333-338.
13. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, and Ni L, et al.; Pharmaceutical Research and Manufacturers of America Drug Metabolism/ Clinical Pharmacology Technical Working Groups (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469.
14. Boecker BB (2003) Reference values for basic human anatomical and physiological characteristics for use in radiation protection. Radiat Prot Dosimetry 105:571-574.
15. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, and Gescher AJ, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252.
16. Brantley SJ, Graf TN, Oberlies NH, and Paine MF (2013) A systematic approach to evaluate herb-drug interaction mechanisms: Investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos 41:1662-1670.
17. Brantley SJ, Oberlies NH, Kroll DJ, and Paine MF (2010) Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther 332:1081-1087.
18. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, and Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13: 407-484.
19. Brownie S (2005) The development of the US and Australian dietary supplement regulations. What are the implications for product quality? Complement Ther Med 13:191-198.
20. Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, and Foster BC (2007) Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 85:966-978.
21. Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, and Mesecar AD (2010) Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 429: 273-282.
22. Camfield DA, Sarris J, and Berk M (2011) Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 35:887-895.
23. Canistro D, Bonamassa B, Pozzetti L, Sapone A, Abdel-Rahman SZ, Biagi GL, and Paolini M (2009) Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. Food Chem Toxicol 47:454-461.
24. Chan WK and Delucchi AB (2000) Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67:3103-3112.
25. Chang JC, Wu YT, Lee WC, Lin LC, and Tsai TH (2009) Herb-drug interaction of silymarin or silibinin on the pharmacokinetics of trazodone in rats. Chem Biol Interact 182:227-232.
26. Chang TK, Chen J, and Lee WB (2001) Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 299:874-882.
27. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, and Alberts DS (2010) Resveratrol modulates drug-and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168-1175.
28. Chu X, Bleasby K, and Evers R (2013) Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol 9:237-252.
29. Ciolino HP and Yeh GC (1999) Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56:760-767.
30. Ciolino HP, Daschner PJ, and Yeh GC (1998) Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58:5707-5712.
31. Clay AT and Sharom FJ (2013) Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. Biochemistry 52:343-354.
32. Colom H, Alfaras I, Maijó M, Juan ME, and Planas JM (2011) Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats. Pharm Res 28:1606-1621.
33. Cui Y, König J, and Keppler D (2001) Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60:934-943.
34. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
35. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, and Kroll DJ (2005) Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 65:4448-4457.
36. de Lima Toccafondo Vieira M and Huang SM (2012) Botanical-drug interactions: a scientific perspective. Planta Med 78:1400-1415.
37. de Santi C, Pietrabissa A, Mosca F, and Pacifici GM (2000a) Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 30:1047-1054.
38. De Santi C, Pietrabissa A, Spisni R, Mosca F, and Pacifici GM (2000b) Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30:609-617.
39. De Smet PA (2005) Herbal medicine in Europe-relaxing regulatory standards. N Engl J Med 352:1176-1178.
40. Deng JW, Shon JH, Shin HJ, Park SJ, Yeo CW, Zhou HH, Song IS, and Shin JG (2008) Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res 25:1807-1814.
41. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, and Morse G (2003) Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 23: 866-870.
42. Dietary Supplement Health and Education Act (1994) Public Law 103-417, 103rd Congress.
43. Doehmer J, Tewes B, Klein KU, Gritzko K, Muschick H, and Mengs U (2008) Assessment of drug-drug interaction for silymarin. Toxicol In Vitro 22:610-617.
44. Doehmer J, Weiss G, McGregor GP, and Appel K (2011) Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro 25:21-27.
45. Ebert B, Seidel A, and Lampen A (2007) Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci 96:227-236.
46. Efferth T and Koch E (2011) Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 12:122-132.
47. El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, Mikhail N, Hashem M, Mousa A, and Aboul-Fotouh A, et al. (2009) A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine 16:391-400.
48. Etheridge AS, Black SR, Patel PR, So J, and Mathews JM (2007) An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73:731-741.
49. European Medicines Agency (2012) Guideline on the Investigation of Drug Interactions, European Medicines Agency, London, UK.
50. European Parliament (2002) Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. Official J Eur Union 183:51-57.
51. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, and Glodé LM (2007) A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 25:139-146.
52. Forte JS and Raman A (2000) Regulatory issues relating to herbal products-part 1: legislation in the European Union, North America, and Australia. J Med Food 3:23-39.
53. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, and Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group (2012) Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 308:274-282.
54. Fuhr U, Beckmann-Knopp S, Jetter A, Lück H, and Mengs U (2007) The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 73:1429-1435.
55. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, and Bombardier C; CONSORT Group (2006) Recommendations for reporting randomized controlled trials of herbal interventions: Explanation and elaboration. J Clin Epidemiol 59:1134-1149.
56. Gardiner P, Graham RE, Legedza AT, Eisenberg DM, and Phillips RS (2006) Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 166: 1968-1974.
57. Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, and Amirghofran Z (2009) Combined therapy of silymarin and desferrioxamine in patients with betathalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol 23: 359-365.
58. Goldberg DM, Yan J, and Soleas GJ (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79-87.
59. Goldman P (2001) Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 135:594-600.
60. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, and Roberts SK (2006) Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 21:275-280.
61. Graf TN, Wani MC, Agarwal R, Kroll DJ, and Oberlies NH (2007) Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med 73:1495-1501.
62. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, and Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
63. Gunaratna C and Zhang T (2003) Application of liquid chromatography- electrospray ionizationion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes. J Chromatogr B Analyt Technol Biomed Life Sci 794:303-310.
64. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, and Cheboyina S (2006a) Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 46:201-213.
65. Gurley BJ (2012) Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements. Planta Med 78:1478-1489.
66. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, and Cheboyina S (2006b) Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 34:69-74.
67. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, and Shah A (2004) In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 76:428-440.
68. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, and Battu SK (2008) Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 52:755-763.
69. Han HK (2011) Role of transporters in drug interactions. Arch Pharm Res 34:1865-1877.
70. Han Y, Guo D, Chen Y, Tan ZR, and Zhou HH (2009a) Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica 39:694-699.
71. Han Y, Guo D, Chen Y, Chen Y, Tan ZR, and Zhou HH (2009b) Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol 65:585-591.
72. Harper JN and Wright SH (2013) Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am J Physiol Renal Physiol 304:F56-F67.
73. Health Canada (2006) Evidence for Safety and Efficacy of Finished Natural Health Products, Natural Health Products Directorate, Health Canada, Ottawa, ON.
74. Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, Crowell JA, Levine BS, and Kong AN (2005) Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299-2314.
75. Hewitt NJ, Lecluyse EL, and Ferguson SS (2007) Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196-1224.
76. Hollenberg PF (2002) Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 34:17-35.
77. Hong SP, Choi DH, and Choi JS (2008) Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. Cardiovasc Ther 26:269-275.
78. Hoshino J, Park EJ, Kondratyuk TP, Marler L, Pezzuto JM, van Breemen RB, Mo S, Li Y, and Cushman M (2010) Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 53:5033-5043.
79. Huang SM (2012) PBPK as a tool in regulatory review. Biopharm Drug Dispos 33:51-52.
80. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, and Raza M (2006) The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 20: 1036-1039.
81. Iwuchukwu OF and Nagar S (2008) Resveratrol (trans-resveratrol, 3,5,49-trihydroxy-transstilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos 36:322-330.
82. Iwuchukwu OF, Sharan S, Canney DJ, and Nagar S (2012) Analytical method development for synthesized conjugated metabolites of trans-resveratrol, and application to pharmacokinetic studies. J Pharm Biomed Anal 63:1-8.
83. Iwuchukwu OF, Tallarida RJ, and Nagar S (2011) Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells. Life Sci 88:1047-1054.
84. Jancová P, Anzenbacherová E, Papousková B, Lemr K, Luzná P, Veinlichová A, Anzenbacher P, and Simánek V (2007) Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 35:2035-2039.
85. Jancová P, Siller M, Anzenbacherová E, Kren V, Anzenbacher P, and Simánek V (2011) Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases. Xenobiotica 41:743-751.
86. Kalgutkar AS, Obach RS, and Maurer TS (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drugdrug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407-447.
87. Kato M, Chiba K, Horikawa M, and Sugiyama Y (2005) The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20:236-243.
88. Kennedy J, Wang CC, and Wu CH (2008) Patient Disclosure about Herb and Supplement Use among Adults in the US. Evid Based Complement Alternat Med 5:451-456.
89. Khalil F and Läer S (2011) Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 2011:907461.
90. Kim CS, Choi SJ, Park CY, Li C, and Choi JS (2010) Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res 30:79-85.
91. Kim E, Sy-Cordero A, Graf TN, Brantley SJ, Paine MF, and Oberlies NH (2011a) Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes. Planta Med 77:265-270.
92. Kim JH, Chen C, and Tony Kong AN (2011b) Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Arch Biochem Biophys 512:160-166.
93. Kim NC, Graf TN, Sparacino CM, Wani MC, and Wall ME (2003a) Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem 1:1684-1689.
94. Kim YC, Kim EJ, Lee ED, Kim JH, Jang SW, Kim YG, Kwon JW, Kim WB, and Lee MG (2003b) Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther 41:593-596.
95. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, Sugiyama Y, and Lai Y (2013) Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 9:3535-3542.
96. Kindla J, Müller F, Mieth M, Fromm MF, and König J (2011) Influence of non-steroidal antiinflammatory drugs on organic anion transporting polypeptide (OATP) 1B1-and OATP1B3-mediated drug transport. Drug Metab Dispos 39:1047-1053.
97. Kis E, Ioja E, Nagy T, Szente L, Herédi-Szabó K, and Krajcsi P (2009) Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors. Drug Metab Dispos 37:1878-1886.
98. Kock K, Xie Y, Oberlies NH, Hawke RL, and Brouwer KL (2013) Interaction of silymarin flavonolignans with organic anion transporting polypeptides (OATPs). Drug Metab Dispos 41: 958-965.
99. Kopp P (1998) Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 138:619-620.
100. Kosina P, Maurel P, Ulrichová J, and Dvorák Z (2005) Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Mol Toxicol 19:149-153.
101. Kroll DJ, Shaw HS, and Oberlies NH (2007) Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6:110-119.
102. Kundu JK and Surh YJ (2008) Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 269:243-261.
103. Kunze KL, Eddy AC, Gibaldi M, and Trager WF (1991) Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 3:24-29.
104. Ladas EJ, Kroll DJ, Oberlies NH, Cheng B, Ndao DH, Rheingold SR, and Kelly KM (2010) A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 116:506-513.
105. Lançon A, Hanet N, Jannin B, Delmas D, Heydel JM, Lizard G, Chagnon MC, Artur Y, and Latruffe N (2007) Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos 35:699-703.
106. Lee JY, Duke RK, Tran VH, Hook JM, and Duke CC (2006) Hyperforin and its analogues inhibit CYP3A4 enzyme activity. Phytochemistry 67:2550-2560.
107. Lee KS, Chae SW, Park JH, Park JH, Choi JM, Rhie SJ, and Lee HJ (2013) Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. Xenobiotica 43:303-310.
108. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, and Shi X (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309:1017-1026.
109. Li X and Choi JS (2009) Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res 29:1411-1415.
110. Li Y, Lu J, and Paxton JW (2012) The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics. Curr Drug Metab 13:624-639.
111. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
112. Lin LC, Wang MN, and Tsai TH (2008) Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem Biol Interact 174:177-182.
113. Lindstrom A, Ooyen C, Lynch M, and Blumenthal M (2013) Herb supplement sales increase 5.5% in 2012: herbal supplement sales rise for 9th consecutive year; turmeric sales jump 40% in natural channel. HerbalGram 99:60-65.
114. Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, and Brouwer KL (1999) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12-G21.
115. Maier-Salamon A, Hagenauer B, Reznicek G, Szekeres T, Thalhammer T, and Jäger W (2008) Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. J Pharm Sci 97:1615-1628.
116. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, and Ducharme MP (2002) Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302: 369-373.
117. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
118. McBride A, Augustin KM, Nobbe J, and Westervelt P (2012) Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia. J Oncol Pharm Pract 18:360-365.
119. Ménez C, Mselli-Lakhal L, Foucaud-Vignault M, Balaguer P, Alvinerie M, and Lespine A (2012) Ivermectin induces P-glycoprotein expression and function through mRNA stabilization in murine hepatocyte cell line. Biochem Pharmacol 83:269-278.
120. Mengs U, Pohl RT, and Mitchell T (2012) Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol 13:1964-1970.
121. Mikstacka R, Baer-Dubowska W, Wieczorek M, and Sobiak S (2008) Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities. Mol Nutr Food Res 52 (Suppl 1): S77-S83.
122. Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, and Phillips E, et al. (2005) Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 61:1-7.
123. Miura D, Miura Y, and Yagasaki K (2003) Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 73:1393-1400.
124. Mohamed ME and Frye RF (2011) Inhibitory effects of commonly used herbal extracts on UDPglucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab Dispos 39: 1522-1528.
125. Mohamed MF, Tseng T, and Frye RF (2010) Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. Xenobiotica 40:663-669.
126. Molina H, Azocar L, Ananthanarayanan M, Arrese M, and Miquel JF (2008) Localization of the Sodium-Taurocholate cotransporting polypeptide in membrane rafts and modulation of its activity by cholesterol in vitro. Biochim Biophys Acta 1778:1283-1291.
127. Moltó J, Valle M, Miranda C, Cedeño S, Negredo E, and Clotet B (2012) Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother 56:2837-2841.
128. Moon YJ and Morris ME (2007) Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats. Mol Pharm 4: 865-872.
129. Nguyen H, Zhang S, and Morris ME (2003) Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 92:250-257.
130. Novak RF and Woodcroft KJ (2000) The alcohol-inducible form of cytochrome P450 (CYP 2E1): role in toxicology and regulation of expression. Arch Pharm Res 23:267-282.
131. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
132. Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294: 88-95.
133. Okey AB (1990) Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 45: 241-298.
134. Otake Y, Nolan AL, Walle UK, and Walle T (2000) Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol 73:265-270.
135. Paine MF and Oberlies NH (2007) Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 3:67-80.
136. Patel J, Buddha B, Dey S, Pal D, and Mitra AK (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11:262-277.
137. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, and Brown K (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215:161-169.
138. Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, Peck-Radosavljevic M, and Ferenci P (2010) Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol 49: 131-133.
139. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, and Falloon J (2002) Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 22: 551-556.
140. Piver B, Berthou F, Dreano Y, and Lucas D (2003) Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci 73:1199-1213.
141. Planas JM, Alfaras I, Colom H, and Juan ME (2012) The bioavailability and distribution of transresveratrol are constrained by ABC transporters. Arch Biochem Biophys 527:67-73.
142. Post-White J, Ladas EJ, and Kelly KM (2007) Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther 6:104-109.
143. Poulin P and Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35.
144. Rambaldi A, Jacobs BP, and Gluud C (2007) Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev (4):CD003620.
145. Rao BN, Srinivas M, Kumar YS, and Rao YM (2007) Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metabol Drug Interact 22: 175-185.
146. Raucy JL, Lasker J, Ozaki K, and Zoleta V (2004) Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci 79:233-241.
147. Rodgers T and Rowland M (2007) Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918-933.
148. Roth M, Araya JJ, Timmermann BN, and Hagenbuch B (2011) Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae). J Pharmacol Exp Ther 339:624-632.
149. Rousseaux CG and Schachter H (2003) Regulatory issues concerning the safety, efficacy and quality of herbal remedies. Birth Defects Res B Dev Reprod Toxicol 68:505-510.
150. Rowland M, Peck C, and Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73.
151. Ruotolo R, Calani L, Fietta E, Brighenti F, Crozier A, Meda C, Maggi A, Ottonello S, and Del Rio D (2013) Anti-estrogenic activity of a human resveratrol metabolite. Nutr Metab Cardiovasc Dis 23:1086-1092.
152. Sayyah M, Boostani H, Pakseresht S, and Malayeri A (2010) Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder. Prog Neuropsychopharmacol Biol Psychiatry 34:362-365.
153. Schandalik R, Gatti G, and Perucca E (1992) Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 42:964-968.
154. Schandalik R and Perucca E (1994) Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. Drugs Exp Clin Res 20:37-42.
155. Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, and Hawke RL (2008) The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 36: 1909-1916.
156. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, and Di Bisceglie AM, et al.; HALT-C Trial Group (2008) Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALTC) Trial. Hepatology 47:605-612.
157. Sharan S, Iwuchukwu OF, Canney DJ, Zimmerman CL, and Nagar S (2012) In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide. Drug Metab Dispos 40:1993-2001.
158. Shi S and Klotz U (2012) Drug interactions with herbal medicines. Clin Pharmacokinet 51: 77-104.
159. Silano V, Coppens P, Larrañaga-Guetaria A, Minghetti P, and Roth-Ehrang R (2011) Regulations applicable to plant food supplements and related products in the European Union. Food Funct 2:710-719.
160. Silverman RB (1995) [10] Mechanism-based enzyme inactivators. Methods Enzymol 249: 240-283.
161. Smoliga JM, Baur JA, and Hausenblas HA (2011) Resveratrol and health-a comprehensive review of human clinical trials. Mol Nutr Food Res 55:1129-1141.
162. Song JH and Choi HJ (2011) Silymarin efficacy against influenza A virus replication. Phytomedicine 18:832-835.
163. Sridar C, Goosen TC, Kent UM, Williams JA, and Hollenberg PF (2004) Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 32:587-594.
164. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3-and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
165. Tamaki H, Satoh H, Hori S, Ohtani H, and Sawada Y (2010) Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab Pharmacokinet 25:170-179.
166. Tatsis EC, Boeren S, Exarchou V, Troganis AN, Vervoort J, and Gerothanassis IP (2007) Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/ MS. Phytochemistry 68:383-393.
167. Tracy TS (2006) Atypical cytochrome p450 kinetics: implications for drug discovery. Drugs R D 7:349-363.
168. Troutman MD and Thakker DR (2003) Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20:1210-1224.
169. Tsai HH, Lin HW, Lu YH, Chen YL, and Mahady GB (2013) A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines. PLoS ONE 8:e64255.
170. Tyapochkin E, Kumar VP, Cook PF, and Chen G (2011) Reaction product affinity regulates activation of human sulfotransferase 1A1 PAP sulfation. Arch Biochem Biophys 506:137-141.
171. Tyler VE (2000) Herbal medicine: from the past to the future. Public Health Nutr 3 (4A): 447-452.
172. Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, and Miners JO (2008) Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol 74:1152-1162.
173. Ung D and Nagar S (2009) Trans-resveratrol-mediated inhibition of beta-oestradiol conjugation in MCF-7 cells stably expressing human sulfotransferases SULT1A1 or SULT1E1, and human liver microsomes. Xenobiotica 39:72-79.
174. Upadhyay G, Singh AK, Kumar A, Prakash O, and Singh MP (2008) Resveratrol modulates pyrogallol-induced changes in hepatic toxicity markers, xenobiotic metabolizing enzymes and oxidative stress. Eur J Pharmacol 596:146-152.
175. US Food and Drug Administration (2012) Draft Guidance: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, US Food and Drug Administration, Rockville, MD.
176. Václavíková R, Horský S, Simek P, and Gut I (2003) Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol 368:200-209.
177. van de Wetering K, Burkon A, Feddema W, Bot A, de Jonge H, Somoza V, and Borst P (2009) Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 75: 876-885.
178. van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, and Gelderblom H (2005) Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 11:7800-7806.
179. Venkatakrishnan K, Obach RS, and Rostami-Hodjegan A (2007) Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37:1225-1256.
180. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, and Strom SC (2000) Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 28:1270-1273.
181. Vidlar A, Vostalova J, Ulrichova J, Student V, Krajicek M, Vrbkova J, and Simanek V (2010) The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy-a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:239-244.
182. Walle T, Hsieh F, DeLegge MH, Oatis JE, Jr, and Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382.
183. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, and Redfield R (2004) Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci 93:2448-2457.
184. Wang X and Morris ME (2007) Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos 35:268-274.
185. Wang Y, Catana F, Yang Y, Roderick R, and van Breemen RB (2002) An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 50:431-435.
186. Weber CC, Kressmann S, Fricker G, and Müller WE (2004) Modulation of P-glycoprotein function by St John's wort extract and its major constituents. Pharmacopsychiatry 37:292-298.
187. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, Zhang HY, and Li YW (2013) Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 32:657-669.
188. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, and Smith PC (2008) Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36:65-72.
189. Wenzel E, Soldo T, Erbersdobler H, and Somoza V (2005) Bioactivity and metabolism of transresveratrol orally administered to Wistar rats. Mol Nutr Food Res 49:482-494.
190. Weyhenmeyer R, Mascher H, and Birkmayer J (1992) Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol 30:134-138.
191. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
192. Winslow LC and Kroll DJ (1998) Herbs as medicines. Arch Intern Med 158:2192-2199.
193. Won CS, Oberlies NH, and Paine MF (2012) Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther 136:186-201.
194. Wu JW and Tsai TH (2007) Effect of silibinin on the pharmacokinetics of pyrazinamide and pyrazinoic acid in rats. Drug Metab Dispos 35:1603-1610.
195. You G and Morris ME (2007) Drug Transporters: Molecular Characterization and Role in Drug Disposition, Wiley-Interscience, Hoboken, NJ.
196. Yu C, Shin YG, Kosmeder JW, Pezzuto JM, and van Breemen RB (2003) Liquid chromatography/ tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 17:307-313.
197. Zhang S and Morris ME (2003a) Effect of the flavonoids biochanin A and silymarin on the Pglycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 20:1184-1191.
198. Zhang S and Morris ME (2003b) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258-1267.
199. Zhang S, Yang X, and Morris ME (2004) Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 21:1263-1273.
200. Zhao P, Rowland M, and Huang SM (2012) Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 92:17-20.
201. Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Patrick KS, and Markowitz JS (2013) An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study. Drug Metab Dispos 41:1679-1685.
202. Zuber R, Modrianský M, Dvorák Z, Rohovský P, Ulrichová J, Simánek V, and Anzenbacher P (2002) Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 16:632-638.